Karyopharm's FDA Accelerated Approval For Cancer Drug Isn't The Only One On Deck [Seeking Alpha]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Seeking Alpha
Karyopharm's FDA Accelerated Approval For Cancer Drug Isn't The Only One On Deck Summary Karyopharm Therapeutics receives FDA accelerated approval for selinexor to treat patients with penta-refractory multiple myeloma. There is potential for European approval of selinexor for penta-refractory multiple myeloma that is expected by the end of 2019. The global MM therapeutics market opportunity is expected to reach $37.5 billion by 2024. Karyopharm has potential to file accelerated approval for another indication known as relapsed/refractory diffuse large B-cell lymphoma, but that depends upon how well the meeting goes with the FDA in the second half of 2019. KPTI Accelerated Approval In Very Hard To Treat Patient Population received accelerated approval from the FDA for selinexor Multiple Myeloma is a type of cancer The ability for Karyopharm to receive accelerated approval is testament to the clinical data produced in this tough to treat patient population. The reason why selinexor was
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Florida Cancer Specialists & Research Institute Shares Pharmacy Expertise To Advance Medically Integrated Oncology Care [Yahoo! Finance]Yahoo! Finance
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor) [Yahoo! Finance]Yahoo! Finance
- Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)Business Wire
- Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences [Yahoo! Finance]Yahoo! Finance
KPTI
Earnings
- 2/29/24 - Miss
KPTI
Sec Filings
- 4/19/24 - Form ARS
- 4/19/24 - Form DEFA14A
- 4/19/24 - Form DEF
- KPTI's page on the SEC website